FDA-filed SPL labeling · retrieved through openFDA

Treprostinil

Treprostinil is a prostacyclin-based medicine used to treat pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), available in inhaled, oral, and injectable forms.

Brand names OrenitramTyvasoRemodulinYutrepiaTyvaso DPI +1 more
Drug class ⓘ Prostacycline Vasodilator
Rx Forms 3 Routes Intravenous; Subcutaneous · Oral · Intravenous, Subcutaneous · Respiratory (inhalation)
Dr. Brian Staiger, PharmD, BCPS
Reviewed by Last reviewed Jul 10, 2026
🧬 Where this information comes from Click to expand

The clinical label records used on this page are FDA-filed Structured Product Labeling (SPL) retrieved through openFDA. We identified 5 clinical label sets within the page’s selected clinical scope after exact ingredient or ingredient-combination matching and applicable route/form matching. Forms, routes, brands, labelers, strengths, and NDC product-record counts are built separately from matching FDA National Drug Code Directory records. The linked DailyMed document is a representative official source for verification, not the page’s only clinical source. View the linked label on DailyMed →

At a glance
Linked label effectiveApr 6, 2023
Clinical labels in scope ⓘ5
AvailabilityRx
Earliest approval/marketing year ⓘ2002
FDA-listed product records ⓘ151
Boxed warningNone found in compared labels
How we combine label and product data →
✓No current FDA shortage listed · checked Sep 21, 2026
Other forms & routes:
Injection Oral inhalation
⭐ Treprostinil at a glance The quick version — the full detail is in the Patient Information Guide below.
💊
HelloPharmacist Editorial Team Bottom Line
Treprostinil is a serious, carefully managed medicine for pulmonary arterial hypertension and related lung-pressure conditions, available in inhaled, oral tablet, and continuous-infusion forms — each with its own dosing approach and safety considerations. The biggest risks are bloodstream infections with IV use and a dangerous rebound if the drug is stopped suddenly, so never adjust your dose without your care team. Work closely with your prescriber to find the right form and dose for your situation.
How we write & review this content — our editorial policy →

📖 Treprostinil: Patient Information Guide

A plain-language walkthrough of Treprostinil — what it treats, how it works, how it’s taken, side effects, warnings and interactions. Tap any section to expand it.

🎯What it's used for▾

Treprostinil is approved for use across several products and routes. Here is the full set of supported indications:

  • Pulmonary arterial hypertension (PAH; WHO Group 1) — improving exercise ability: Supported by Tyvaso, Tyvaso DPI, Yutrepia (inhaled), and treprostinil injection / Remodulin (subcutaneous or IV)
  • PAH (WHO Group 1) — delaying disease progression and improving exercise capacity: Orenitram (extended-release oral tablet) only
  • PAH (WHO Group 1) — transitioning patients from epoprostenol: Treprostinil injection and Remodulin only
  • Pulmonary hypertension associated with interstitial lung disease (PH-ILD; WHO Group 3) — improving exercise ability: Tyvaso, Tyvaso DPI, and Yutrepia (inhaled forms) only
⚙️How it works▾

Treprostinil mimics a natural substance in the body called prostacyclin. It works by directly relaxing and widening the blood vessels in the lungs and throughout the body, which lowers the pressure the heart has to pump against. It also reduces the tendency of platelets (the tiny blood cells that form clots) to clump together, and may help slow the abnormal thickening of blood vessel walls that characterizes PAH.

💊How it's taken▾

How treprostinil is taken varies significantly by product — always follow your prescriber's specific instructions.

  • Orenitram (tablet): Taken by mouth with food, multiple times per day; tablets must be swallowed whole
  • Tyvaso (inhaled solution): Inhaled using the Tyvaso Inhalation System in 4 sessions per day, spaced about 4 hours apart during waking hours
  • Tyvaso DPI (inhaled powder): Inhaled using the Tyvaso DPI Inhaler in 4 sessions per day, approximately 4 hours apart
  • Yutrepia (inhaled capsule): Inhaled — not swallowed — using the supplied device, 3 to 5 times per day
  • Remodulin / treprostinil injection: Given as a continuous infusion under the skin or into a vein, around the clock; doses are increased gradually

Never stop treprostinil suddenly or miss large portions of your dose without speaking to your doctor first — abrupt changes can be dangerous.

🤒Side effects — in detail▾

Side effects vary by route, but here are the most commonly reported ones across treprostinil products:

  • Infusion site pain and skin reaction (most common with subcutaneous injection; can be severe)
  • Headache
  • Diarrhea
  • Nausea
  • Jaw pain
  • Flushing or vasodilation (warmth, skin redness)
  • Swelling (edema)
  • Low blood pressure (hypotension)
  • Rash

Seek prompt medical attention if you develop signs of a bloodstream infection (fever, chills, feeling very unwell) with IV use, experience significant dizziness or fainting from low blood pressure, or notice unusual bleeding.

⚠️Warnings & precautions▾
  • Risk of serious bloodstream infection with IV use: Long-term IV infusion through a central venous catheter carries a risk of life-threatening blood infections and sepsis. Subcutaneous infusion is preferred for this reason. Watch for fever, chills, or sudden worsening and seek care immediately.
  • Never stop abruptly: Suddenly stopping or sharply reducing the dose can cause a rapid, dangerous worsening of PAH symptoms. Any dose changes must be made with medical guidance.
  • Low blood pressure risk: Treprostinil widens blood vessels throughout the body, which can cause symptomatic low blood pressure — especially in patients who already have low systemic blood pressure.
  • Increased bleeding risk: Because treprostinil inhibits platelet aggregation (clumping), it can increase the tendency to bleed. Report unusual bruising or bleeding to your doctor.
  • Liver disease caution: In patients with liver problems, treprostinil clears much more slowly, leading to higher drug levels and greater risk of side effects. Dose must be adjusted carefully; use is contraindicated in severe liver impairment.
🔀What it interacts with▾

Treprostinil can be affected by certain other medicines — tell your prescriber and pharmacist everything you take:

  • Gemfibrozil (cholesterol medicine): Blocks the liver enzyme (CYP2C8) that clears treprostinil, roughly doubling drug levels — a significant interaction requiring medical attention
  • Rifampin (antibiotic): Speeds up treprostinil clearance through the same enzyme, reducing how much is in your body and potentially making it less effective
  • Blood pressure medicines and other vasodilators: Can add to treprostinil's blood pressure-lowering effect, increasing the risk of hypotension
  • Warfarin (blood thinner): Treprostinil does not appear to change warfarin levels or its INR effect, but treprostinil's own platelet-inhibiting action means bleeding risk should still be monitored
  • Bosentan and sildenafil: No significant pharmacokinetic interaction found in studies; these are frequently prescribed alongside treprostinil but your full medicine list should always be reviewed by your care team

This is not a complete list of interactions. Always talk with your doctor or pharmacist before starting, stopping, or changing any medication.

📋Before taking it▾
  • Severe liver impairment (Child-Pugh Class C): Treprostinil is contraindicated — it cannot be used safely
  • Moderate liver impairment: Orenitram should be avoided; other forms require extra caution and lower starting doses
  • Mild liver impairment: Use with caution; lower starting doses and slow titration are required
  • Pregnancy: Animal studies showed fetal harm at relatively low doses; PAH in pregnancy itself carries serious risks to mother and baby — discuss risks and benefits carefully with your doctor before or if you become pregnant
  • Breastfeeding: It is unknown whether treprostinil passes into human milk; discuss with your doctor
  • Children: Safety and effectiveness have not been established in pediatric patients
  • Older adults: Higher rates of side effects have been observed; dose selection should be cautious, accounting for possible reduced liver or heart function
  • Kidney disease: No dose adjustment is required; treprostinil is not removed by dialysis
🚑If you take too much▾

Too much treprostinil causes an exaggerated version of its normal effects: flushing, headache, low blood pressure, nausea, vomiting, and diarrhea. In serious cases — particularly if a large accidental dose is delivered through an IV catheter — severe low blood pressure, near-fainting, or seizure-like activity can occur. Most overdose events in clinical trials resolved when the infusion was slowed or stopped. If you suspect an overdose, seek emergency medical care immediately.

📡Pharmacodynamics — effects in the body▾

In the body, treprostinil relaxes the walls of blood vessels, lowering the resistance the heart pumps against and allowing cardiac output (the amount of blood the heart pumps) to increase. It can also cause the heart to beat faster (tachycardia). At high doses, it may reduce the strength and relaxation speed of heart muscle contractions. No major effects on the heart's electrical conduction system have been observed.

🔬Pharmacokinetics — how your body processes it▾

When given by subcutaneous infusion, treprostinil is almost completely absorbed, reaching steady drug levels in roughly 10 hours. It is about 91% bound to proteins in the blood and is broken down primarily in the liver by an enzyme called CYP2C8. Most of the drug and its inactive breakdown products leave the body through the urine. The drug's half-life — the time it takes for the body to clear half of it — is approximately 4 hours after subcutaneous dosing. In patients with liver disease, clearance can be reduced by up to 80%, causing drug levels to build much higher than normal.

📄 Written from Treprostinil’s FDA-approved label information, summarized in plain language with AI, and reviewed by our pharmacy team before publication. Every point is grounded in that labeling — nothing is invented. How we use AI →

291

Supplements & herbs that interact with Treprostinil

291 supplements and herbal products have documented interactions with Treprostinil in the licensed clinical database we use. Most are manageable — but your pharmacist should know about everything you take, including vitamins and herbals.

Severity mix
  • Major · 6
  • Moderate · 258
  • Minor · 27
ACTIVATED CHARCOAL Major AMERICAN HELLEBORE Major AMERICAN MISTLETOE Major DANSHEN Major PIRACETAM Major TYRAMINE Major ACONITE Moderate ADRAFINIL Moderate +283 more
Every supplement checked against Treprostinil — ranked by severity The full interaction hub: 6 major · 258 moderate · 27 minor · every one linked to its full report. Check Treprostinil against your exact supplements

Educational information from a licensed clinical database (Natural Medicines) — see our data sources & update cadence. Not medical advice: an interaction being documented does not mean it will happen to you; do not start or stop medications or supplements without professional guidance.

1

Nutrient depletion considerations

Treprostinil has been associated with lower levels of 1 nutrient in the clinical literature. This does not mean a deficiency will occur — it means these may be worth discussing with your pharmacist or healthcare provider, especially with long-term use.

COENZYME Q10 Insufficient Evidence
See the full Treprostinil nutrient depletion report

Educational information from a licensed clinical database (Natural Medicines) — not medical advice. Do not start or stop medications or supplements without professional guidance.

🩺 Pharmacist Counseling Corner

Quick, plain-English answers to the questions patients ask most about Treprostinil — the kind of thing our pharmacy team would talk through with you at the counter.

What exactly is treprostinil and why did my doctor prescribe it? ▾
Treprostinil mimics a natural substance your body makes to keep blood vessel walls relaxed. In pulmonary arterial hypertension (PAH) — and in some lung-disease-related forms of high lung pressure — those vessels become too narrow and stiff, forcing your heart to work dangerously hard. Treprostinil widens those vessels, lowers that pressure, and helps you tolerate activity better. Depending on which product you're on, it may also be aimed at slowing how fast your disease progresses.
I'm on the inhaled version — how often do I need to use it each day? ▾
The inhaled products are all used multiple times per day, spaced out across your waking hours. Tyvaso and Tyvaso DPI are typically used 4 times a day, roughly 4 hours apart. Yutrepia is used 3 to 5 times a day. The timing can be shifted a bit around planned activities since the effect does taper between sessions. Your prescriber and the instructions that come with your device will spell out the exact routine — stick to that schedule as closely as you can.
What side effects should I expect, and which ones mean I need to call someone? ▾
Headache, jaw pain, flushing, nausea, and diarrhea are common and tend to be most noticeable when your dose is being increased. If you're on the subcutaneous (under-the-skin) injection, site pain and redness are very common and can sometimes be quite bothersome. These effects are generally related to the drug relaxing blood vessels and tend to settle over time. Call your doctor or seek emergency care if you feel significantly dizzy or faint from low blood pressure, notice unusual bleeding, or — if you're on IV treprostinil — develop fever, chills, or signs of an infection.
Can I ever just stop taking it if I feel like I need a break? ▾
Please don't stop suddenly on your own — this is one of the most important things to know about treprostinil. Abruptly stopping or sharply cutting the dose can cause your PAH symptoms to worsen quickly and dangerously. If you're having side effects or struggling with the treatment, call your care team and they can help you adjust things safely. Any changes to your dose should always be made with medical guidance.
Are there medicines or supplements I should avoid while taking treprostinil? ▾
Yes — a few are worth flagging. Gemfibrozil, used for cholesterol, can roughly double the amount of treprostinil in your blood, raising the risk of side effects. Rifampin, an antibiotic, can push levels in the opposite direction and make treprostinil less effective. Any medicine that lowers blood pressure can add to treprostinil's own blood pressure-lowering effect. Make sure your full medicine list — including over-the-counter drugs and supplements — is reviewed by your pharmacist or prescriber.
Is it safe to get pregnant or breastfeed while on treprostinil? ▾
This is a really important conversation to have with your doctor before trying to get pregnant. Animal studies showed treprostinil can harm fetal development, and PAH itself carries serious risks during pregnancy — including heart failure, preterm birth, and stillbirth. As for breastfeeding, we don't currently have data on whether treprostinil passes into breast milk. Your care team can help you weigh the risks and benefits based on your specific situation.
Is Treprostinil available over the counter? ▾
Treprostinil is dispensed by prescription according to its FDA labeling, so it isn't sold over the counter. Your prescriber and pharmacist will determine if it's appropriate for you.
When was Treprostinil first available? ▾
Treprostinil has been available in the United States since at least 2002, based on FDA approval history (Drugs@FDA) and product marketing records.
Who makes Treprostinil? ▾
Treprostinil is supplied by 16 manufacturers listed in the FDA NDC Directory, including United Therapeutics Corporation, Alembic Pharmaceuticals Inc., Dr.Reddy's Laboratories Inc.,.

💬 Answers drafted from Treprostinil’s FDA-approved label information, summarized in plain language with AI, and reviewed by our pharmacy team before publication. Grounded in that labeling — nothing is made up. How we use AI →

🧰 Keep exploring

📊Treprostinil supplement interactions291 checked — ranked by severity 🌿Drug & Supplement CheckerTreprostinil vs. vitamins & herbs 💬Ask a PharmacistFree answer, usually < 24h 🔎NDC & pricing lookupFind Treprostinil NDCs & costs 🅰️Browse Drugs A–ZLook up any medication

💊 How Treprostinil comes

Treprostinil is available in 3 forms. Different forms and brands can have different approved uses, doses, schedules, and directions. Follow the instructions for your exact product, and do not switch forms without guidance from your prescriber or pharmacist.

Injection

Into a vein · Under the skin
Brands Remodulin
How this form is used
What it may be used for
  • Remodulin and treprostinil injection are used to treat PAH (WHO Group 1) to reduce symptoms associated with exercise
  • Remodulin and treprostinil injection are used in PAH patients who need to transition from epoprostenol, to slow the rate of disease worsening
Important instructions
  • Remodulin and treprostinil injection are given as a continuous infusion — subcutaneous (under the skin) is the preferred route; intravenous (into a vein) is used when subcutaneous is not tolerated
  • Remodulin may be diluted with Sterile Diluent for Remodulin or a similar approved high-pH glycine diluent; treprostinil injection may be diluted with Sterile Diluent for Treprostinil or a similar approved diluent
  • Doses are started low and increased gradually based on response — never stop or sharply reduce the infusion suddenly
  • When transitioning from epoprostenol, Remodulin or treprostinil injection dose is increased slowly while epoprostenol is decreased, under close medical supervision
Available strengths 12 strengths
1 mg/mL 2 mg/20 mL 2.5 mg/mL 4 mg/20 mL 5 mg/mL 8 mg/20 mL
Show 6 more strengths Show fewer strengths
10 mg/mL 20 mg/20 mL 50 mg/20 mL 100 mg/20 mL 200 mg/20 mL 400 mg/20 mL
59 FDA-listed product records ⓘ

Inhaler

By mouth · Inhaled
Brands Tyvaso Tyvaso DPI Yutrepia
How this form is used
What it may be used for
  • Tyvaso is used to treat pulmonary arterial hypertension (PAH; WHO Group 1) to improve exercise ability
  • Tyvaso is used to treat pulmonary hypertension associated with interstitial lung disease (PH-ILD; WHO Group 3) to improve exercise ability
  • Tyvaso DPI is used to treat PAH (WHO Group 1) and PH-ILD (WHO Group 3) to improve exercise ability
  • Yutrepia is used to treat PAH (WHO Group 1) and PH-ILD (WHO Group 3) to improve exercise ability
Important instructions
  • Tyvaso is used only with the Tyvaso Inhalation System device and is administered in 4 separate sessions per day, spaced approximately 4 hours apart during waking hours
  • Tyvaso DPI is used only with the Tyvaso DPI Inhaler; each cartridge delivers one inhalation, and treatment is given in 4 sessions per day roughly 4 hours apart
  • Yutrepia capsules are for inhalation only using the supplied inhaler — do not swallow them; they are administered 3 to 5 times per day, with each capsule's contents inhaled in 2 breaths
  • Timing of inhaled sessions can be adjusted around planned activities, as effects diminish over the dosing interval
Available strengths 10 strengths
16 mcg 26.5 mcg 32 mcg 48 mcg 53 mcg 64 mcg
Show 4 more strengths Show fewer strengths
79.5 mcg 80 mcg 106 mcg 1.74 mg/2.9 mL
33 FDA-listed product records ⓘ

Extended-release tablet

By mouth
Brands Orenitram
How this form is used
What it may be used for
  • Orenitram is used to treat pulmonary arterial hypertension (PAH; WHO Group 1) to delay disease progression and improve exercise capacity
  • Orenitram was studied mainly in patients with WHO functional class II–III PAH symptoms
Important instructions
  • Orenitram must be taken with food every time
  • Swallow Orenitram tablets whole — do not crush, split, or chew them
  • Orenitram is typically taken multiple times per day; doses are spaced several hours apart as directed by your prescriber
  • If transitioning from IV or subcutaneous Remodulin, Orenitram dose is increased while the infusion is gradually decreased — do not manage this transition on your own
Available strengths 5 strengths
0.125 mg 0.25 mg 1 mg 2.5 mg 5 mg
15 FDA-listed product records ⓘ

📊 Treprostinil across the U.S. market

How Treprostinil appears in the FDA’s National Drug Code Directory — including its dosage forms, strengths, brand names, manufacturers, and FDA-listed product records. These are directory records, not sales or prescription volume.

3
Dose forms ⓘ
16
Manufacturers
6
Brand names
151
FDA-listed product records ⓘ
2002
First marketed ⓘ

FDA-listed product records by dose form (tablet variants merged) — FDA National Drug Code Directory. Record counts are not sales or prescription volume.

Also listed with the FDA, not a patient dose form: Kit (25) · Powder (19) — bulk drug substance sold to compounders/manufacturers and multi-item kits. These aren’t counted in the dose-form total above.

United Therapeutics Corporation61%
Alembic Pharmaceuticals Inc.8%
Dr.Reddy's Laboratories Inc.,5%
Sandoz Inc5%
MSN Laboratories Private Limited4%
Liquidia Technologies, Inc.3%
Other makers14%

Share of FDA-listed product records by manufacturer — FDA National Drug Code Directory. Record counts are not sales or prescription volume.

📈 How widely Treprostinil is used

A general measure of how commonly Treprostinil is prescribed, based on Medicaid — one of the largest public drug programs. The figure below is prescriptions filled in Q1–Q4 2025, summed across every form and brand of the drug.

Think of this as a proxy for how widely Treprostinil is used, drawn from freely available public data. Medicaid is just one program — these numbers don’t include Medicare, other government coverage, or commercial and cash-pay prescriptions, so real-world use is higher than what’s shown here.

15,732
Medicaid prescriptions filled (Q1–Q4 2025)
$215.3M gross Medicaid reimbursement (before mandatory rebates — net cost is lower)

How commonly is Treprostinil prescribed? Of the 1,596 medications we measure, Treprostinil ranks #846 by Medicaid prescriptions — more than 47% of them.

Where Treprostinil ranks among the drugs we measure · Q1–Q4 2025 · neighbors ±5
Total prescriptions — #846 of 1,596
#841 Dalfampridine 16,062 Rx #842 Lemborexant 16,038 Rx #843 Propylthiouracil 15,946 Rx #844 Durvalumab Injection 15,800 Rx #845 Tinidazole 15,770 Rx #846 Treprostinil 15,732 Rx #847 Cisplatin Injection 15,540 Rx #848 Salmeterol Oral Inhala... 15,481 Rx #849 Oxiconazole 15,480 Rx #850 Acetylcysteine 15,447 Rx #851 Lenalidomide 15,430 Rx

Utilization by Treprostinil product

Pick a product to see its own Medicaid numbers. Each chip is one clinical product — a specific strength & dosage form as defined by RxNorm — with brand-name and generic versions combined.

The 10 mg/mL injectable solution is the most-dispensed Treprostinil product — about 23% of these Medicaid prescriptions.

treprostinil 10 MG/ML Injectable Solution Most dispensed

3,624 Medicaid prescriptions (Q1–Q4 2025) 23% of Treprostinil prescriptions shown $51.5M gross reimbursement (before rebates) ≈ $14,224 per prescription (gross)

Summed across the 1 of 6 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 349408

treprostinil 5 MG/ML Injectable Solution

1,680 Medicaid prescriptions (Q1–Q4 2025) 11% of Treprostinil prescriptions shown $14.9M gross reimbursement (before rebates) ≈ $8,859 per prescription (gross)

Summed across the 2 of 6 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 349410

treprostinil 1 MG/ML Injectable Solution

1,550 Medicaid prescriptions (Q1–Q4 2025) 10% of Treprostinil prescriptions shown $5.8M gross reimbursement (before rebates) ≈ $3,772 per prescription (gross)

Summed across the 2 of 6 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 349407

treprostinil 0.6 MG/ML Inhalation Solution

1,521 Medicaid prescriptions (Q1–Q4 2025) 10% of Treprostinil prescriptions shown $31.8M gross reimbursement (before rebates) ≈ $20,879 per prescription (gross)

Summed across the 1 of 4 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 857795

12 HR treprostinil 1 MG Extended Release Oral Tablet

1,383 Medicaid prescriptions (Q1–Q4 2025) 9% of Treprostinil prescriptions shown $12M gross reimbursement (before rebates) ≈ $8,708 per prescription (gross)

Summed across the 1 of 3 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1488674

treprostinil 0.064 MG Inhalation Powder

1,237 Medicaid prescriptions (Q1–Q4 2025) 8% of Treprostinil prescriptions shown $30.9M gross reimbursement (before rebates) ≈ $25,016 per prescription (gross)

Summed across the 1 of 3 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 2602764

12 HR treprostinil 0.25 MG Extended Release Oral Tablet

919 Medicaid prescriptions (Q1–Q4 2025) 6% of Treprostinil prescriptions shown $1.9M gross reimbursement (before rebates) ≈ $2,095 per prescription (gross)

Summed across the 1 of 3 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1488670

12 HR treprostinil 5 MG Extended Release Oral Tablet

885 Medicaid prescriptions (Q1–Q4 2025) 6% of Treprostinil prescriptions shown $29.2M gross reimbursement (before rebates) ≈ $33,027 per prescription (gross)

Summed across the 1 of 3 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1858831

treprostinil 2.5 MG/ML Injectable Solution

783 Medicaid prescriptions (Q1–Q4 2025) 5% of Treprostinil prescriptions shown $4.9M gross reimbursement (before rebates) ≈ $6,197 per prescription (gross)

Summed across the 1 of 6 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 349409

12 HR treprostinil 2.5 MG Extended Release Oral Tablet

782 Medicaid prescriptions (Q1–Q4 2025) 5% of Treprostinil prescriptions shown $9.6M gross reimbursement (before rebates) ≈ $12,241 per prescription (gross)

Summed across the 1 of 3 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1488678

treprostinil 0.048 MG Inhalation Powder

317 Medicaid prescriptions (Q1–Q4 2025) 2% of Treprostinil prescriptions shown $8.4M gross reimbursement (before rebates) ≈ $26,544 per prescription (gross)

Summed across the 1 of 3 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 2602760

12 HR treprostinil 0.125 MG Extended Release Oral Tablet

259 Medicaid prescriptions (Q1–Q4 2025) 2% of Treprostinil prescriptions shown $115,400 gross reimbursement (before rebates) ≈ $446 per prescription (gross)

Summed across the 1 of 3 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1488665

treprostinil 0.032 MG Inhalation Powder

229 Medicaid prescriptions (Q1–Q4 2025) 1% of Treprostinil prescriptions shown $5.6M gross reimbursement (before rebates) ≈ $24,472 per prescription (gross)

Summed across the 1 of 3 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 2602756

treprostinil 0.016 MG Inhalation Powder

105 Medicaid prescriptions (Q1–Q4 2025) <1% of Treprostinil prescriptions shown $2.6M gross reimbursement (before rebates) ≈ $25,136 per prescription (gross)

Summed across the 1 of 3 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 2602751

treprostinil 0.0795 MG Inhalation Powder

65 Medicaid prescriptions (Q3–Q4 2025) <1% of Treprostinil prescriptions shown $1.7M gross reimbursement (before rebates) ≈ $26,806 per prescription (gross)

Summed across the 1 of 1 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 2714670

treprostinil 0.106 MG Inhalation Powder

43 Medicaid prescriptions (Q2–Q4 2025) <1% of Treprostinil prescriptions shown $743,412 gross reimbursement (before rebates) ≈ $17,289 per prescription (gross)

Summed across the 1 of 1 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 2714674

treprostinil 0.053 MG Inhalation Powder

41 Medicaid prescriptions (Q3–Q4 2025) <1% of Treprostinil prescriptions shown $432,802 gross reimbursement (before rebates) ≈ $10,556 per prescription (gross)

Summed across the 1 of 1 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 2714666

treprostinil 0.0265 MG Inhalation Powder

25 Medicaid prescriptions (Q2–Q4 2025) <1% of Treprostinil prescriptions shown $274,301 gross reimbursement (before rebates) ≈ $10,972 per prescription (gross)

Summed across the 1 of 1 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 2714659

Other Treprostinil products — combination packs and listings not yet matched to a specific clinical product (kept visible so every prescription is accounted for)

284 Medicaid prescriptions (Q1–Q4 2025) 2% of Treprostinil prescriptions shown $2.8M gross reimbursement (before rebates) ≈ $9,739 per prescription (gross)

Summed across the 3 of 74 listed NDC products with Medicaid activity.

Shares are of the Medicaid prescriptions shown here. Product grouping follows RxNorm (the National Library of Medicine’s drug terminology), so “one product” means one strength & dosage form regardless of manufacturer. Dollar figures are gross Medicaid reimbursement before mandatory rebates — rebates (often large, especially for brand-name drugs) are confidential, so actual net cost to Medicaid is lower than shown.

Source: Medicaid State Drug Utilization Data (CMS), aggregated by generic ingredient — summed across every NDC (all brands, strengths, salt forms and dosage forms) of Treprostinil, and across all states and both fee-for-service and managed-care claims. A general popularity signal; it excludes Medicare, commercial insurance and cash prescriptions, so it is not total U.S. use. Based on the 23 of 133 listed Treprostinil NDCs with Medicaid activity.

🔍 Compare Treprostinil products

A representative set of FDA-listed product records for Treprostinil — across manufacturers, strengths, and dosage forms, grouped by form with each product’s manufacturer and how the FDA approved it. The same medicine may be made and packaged by different companies, so a single drug can have many directory entries. (It’s also why a refill can look different — a new shape, color, or box — even though it contains the same medication.)

Showing 151 of 151 products — FDA National Drug Code Directory. See every product, package size and price: browse all 151 Treprostinil NDCs →

RxNorm Concept Web — From Ingredient to Every Form and Strength

This page starts with one ingredient concept (IN). The branches below show its dose-form concepts (SCDF), then the available clinical drug and strength concepts (SCD). Combination products remain separate concepts with their own pages.

Ingredient (IN) Treprostinil RxCUI 343048 4 dose forms · 20 strengths
  3. Dose form (SCDF) Inhalation Solution RxCUI 2108557 No current FDA listing
    Clinical drug / strength (SCD) 0.6 MG/ML RxCUI 857795
  4. Dose form (SCDF) Injectable Solution RxCUI 385082 In current FDA listings
    Clinical drug / strength (SCD) 0.4 MG/ML RxCUI 2667756 1 MG/ML RxCUI 349407 2.5 MG/ML RxCUI 349409 5 MG/ML RxCUI 349410 10 MG/ML RxCUI 349408

Look up RxCUI 343048 in the RxCUI Atlas →

RxNorm is the U.S. National Library of Medicine’s normalized drug vocabulary. Its concept hierarchy can include forms that are not currently marketed; the status on each branch compares that concept with current FDA listings. RxCUIs identify vocabulary concepts, not individual packages or manufacturers.

🏷️ Sold under these brand names

Orenitram Tyvaso Remodulin Yutrepia Tyvaso DPI Diluent

🏭 Manufacturers & labelers

United Therapeutics Corporation 92 Alembic Pharmaceuticals Inc. 12 Dr.Reddy's Laboratories Inc., 8 Sandoz Inc 8 MSN Laboratories Private Limited 6 Liquidia Technologies, Inc. 4 Par Pharmaceutical, Inc. 4 Teva Parenteral Medicines, Inc. 4 Chirogate International Inc 3 Nuray Chemicals Private Limited 3 Sthree Chemicals Private Limited 2 EUROAPI Hungary Ltd. 1 Eurofins CDMO Alphora Inc 1 Everlight Chemical Industrial Corporation Kuanyin II Plant 1 TIEN (Tianjin) Pharmaceutical Co. Ltd 1 YS Life Science Co., Ltd. 1

RxNorm drug class

Treprostinil belongs to the Prostacycline Vasodilator class.

Pharmacologic class Prostacycline Vasodilator
Drug family (ATC) Platelet aggregation inhibitors excl. heparin

Classified by RxNorm RxClass — the U.S. National Library of Medicine's standardized drug-classification service (Established Pharmacologic Class from the FDA, the ATC drug family from the WHO, and mechanism of action). Reference only, not medical advice.

🔬 Where this comes from

Core label, product, RxNorm, safety, and utilization data on this page come from the sources identified below. AI-written, editorial, and licensed sections are labeled separately.

📄
FDA-filed drug labels (SPL) Uses, dosing, warnings & side effects from SPL records retrieved through openFDA; the linked representative set can be verified on DailyMed. ✓ Linked label effective Apr 6, 2023
🏭
Forms, brands & labelersAggregated from ingredient-matched FDA National Drug Code Directory product records for Treprostinil.
📈
Real-world reportsThe FDA Adverse Event Reporting System (FAERS), served through openFDA.
🚨
Recalls & shortagesopenFDA drug-enforcement reports and the FDA drug-shortage database.
🧾 Clinical label set — FDA-filed SPL labels retained for Treprostinil after exact ingredient or ingredient-combination matching and applicable route/form matching
Clinical labels in scope
5
NDC products indexed
151
Distinct labelers/manufacturers represented
16
Linked representative label ⓘ
Sandoz Inc
Linked label effective
Apr 6, 2023
Composite sections available
22
Linked SPL Set ID
473297ca-a872-4052-a053-87dc8f0d3c13
Linked SPL Document ID
fe80d00e-9eba-4192-9515-f9a5ad686a53
Open the linked representative label on DailyMed ↗

How we combine label and product data

HelloPharmacist combines public FDA and NLM records; we don’t author the underlying clinical facts. We identified 5 FDA-filed SPL label sets within the page’s selected clinical scope after exact ingredient or ingredient-combination matching and applicable route/form matching. The representative label is the starting point for the displayed reference monograph; the 12 largest stored in-scope SPL records, which may include that representative, are compared section by section, and the longest available version of each section is retained. Forms, routes, brands, labelers, product-listed strengths, and product-record counts are aggregated separately from ingredient-matched FDA NDC Directory records; package records listed above are associated with the linked SPL; and the normalized concept hierarchy comes from NLM RxNorm.

For canonical ingredient pages, bounded product-attributed indication and administration excerpts may be added to the AI evidence, and the generator is instructed to preserve available product, brand, route, and form qualifiers instead of treating one label as universal. Where a section is identified as AI-written, its plain-language text is generated from bounded label evidence. New draft drug pages remain in the admin review queue before first publication. Sandoz Inc is the representative DailyMed label linked for verification and dates; it is not the sole source used for the page.

This is general education, not medical advice — always consult your doctor or pharmacist about your medications and any medical condition. For the exact wording of the linked representative label, view that label on DailyMed; some displayed composite sections may come from other in-scope SPL labels. Learn how we use AI and our data sources & update cadence.